• About
    • About Sutro
    • Patient Resources
    • Partnerships
    • Corporate Presentation
  • Leadership
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Technology
    • XpressCF® and XpressCF+™ Platforms
    • Antibody-Drug Conjugates and IADCs
    • Bispecific and Engineered Antibodies
    • cGMP Facility
  • Investors
    • Company Presentation
    • Stock
    • Financials
    • Governance
    • Contact IR
    • Email Alerts
  • Pipeline
  • News
    • News Releases
    • Clinical / Scientific Presentation and Publication Highlights
    • Events
    • Events Audio Replays
  • Careers and Culture
    • The Way We Work
    • Join Our Team
    • Diversity, Inclusion and Social Justice
    • Internships
    • Sutroites
  • Contact Us

Changing the future of Oncology.

Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020

Apr 27, 2020

Dr. Wendel Naumann of The Levine Cancer Institute, Non-Audio Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020

Download Non-Audio Presentation CLICK HERE

Sutro Biopharma

310 Utah Ave Suite 150
South San Francisco, CA 94080
650-392-8412

 

Map

Tweets by @sutrobio

Contact Us

General Inquires:
general@sutrobio.com
Business Inquires:
busdev@sutrobio.com
Investor Relations Inquires:
IR@sutrobio.com 
Careers:
jobs@sutrobio.com

© 2021 Sutro Biopharma, Inc. -- Privacy Policy
  • Follow
  • Follow
  • Follow